Oral idasanutlin in patients with polycythemia vera.
Administration, Oral
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
/ administration & dosage
Biomarkers
Female
Humans
Male
Middle Aged
Molecular Targeted Therapy
Mutation
Polycythemia Vera
/ diagnosis
Proto-Oncogene Proteins c-mdm2
/ antagonists & inhibitors
Pyrrolidines
/ administration & dosage
Treatment Outcome
para-Aminobenzoates
/ administration & dosage
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
08 08 2019
08 08 2019
Historique:
received:
21
12
2018
accepted:
30
05
2019
pubmed:
7
6
2019
medline:
15
1
2020
entrez:
7
6
2019
Statut:
ppublish
Résumé
A limited number of drugs are available to treat patients with polycythemia vera (PV) and essential thrombocythemia (ET). We attempted to identify alternative agents that may target abnormalities within malignant hematopoietic stem (HSCs) and progenitor cells (HPCs). Previously, MDM2 protein levels were shown to be upregulated in PV/ET CD34
Identifiants
pubmed: 31167802
pii: S0006-4971(20)42360-2
doi: 10.1182/blood.2018893545
pmc: PMC6688433
doi:
Substances chimiques
Antineoplastic Agents
0
Biomarkers
0
Pyrrolidines
0
RG7388
0
para-Aminobenzoates
0
MDM2 protein, human
EC 2.3.2.27
Proto-Oncogene Proteins c-mdm2
EC 2.3.2.27
Banques de données
ClinicalTrials.gov
['NCT02407080']
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
525-533Subventions
Organisme : NCI NIH HHS
ID : P01 CA108671
Pays : United States
Organisme : NHLBI NIH HHS
ID : P01 HL053762
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA054174
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 by The American Society of Hematology.
Références
Biol Blood Marrow Transplant. 2007 Jan;13(1 Suppl 1):64-72
pubmed: 17222772
Clin Cancer Res. 2013 Jan 1;19(1):34-41
pubmed: 23262034
Clin Cancer Res. 2016 Feb 15;22(4):868-76
pubmed: 26459177
Blood. 2014 Jul 31;124(5):771-9
pubmed: 24869939
Blood. 2012 Feb 9;119(6):1363-9
pubmed: 22160617
Leukemia. 1993 Jul;7(7):946-53
pubmed: 8321046
Sci Rep. 2018 Jan 25;8(1):1610
pubmed: 29371613
Nature. 2015 Oct 1;526(7571):75-81
pubmed: 26432246
Leukemia. 2016 Apr;30(4):776-81
pubmed: 26601783
Exp Hematol. 2015 Aug;43(8):599-608
pubmed: 26209551
Clin Cancer Res. 2014 Jul 15;20(14):3742-52
pubmed: 24812409
Blood. 2012 Oct 11;120(15):3098-105
pubmed: 22872685
Bioinformatics. 2012 Jul 15;28(14):1838-44
pubmed: 22569178
Oncogene. 2012 Mar 8;31(10):1323-33
pubmed: 21785463
Haematologica. 2017 Jan;102(1):e11-e14
pubmed: 27742771
Blood. 2013 Jun 6;121(23):4778-81
pubmed: 23591792
Haematologica. 2016 May;101(5):e185-8
pubmed: 26869629
Clin Cancer Res. 2008 Sep 1;14(17):5318-24
pubmed: 18765522
Cancer Res. 2013 Apr 15;73(8):2587-97
pubmed: 23400593
Leukemia. 2018 Feb;32(2):450-461
pubmed: 28744014
N Engl J Med. 2011 Feb 3;364(5):488-90
pubmed: 21288114
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Nat Rev Cancer. 2013 Feb;13(2):83-96
pubmed: 23303139
Mol Cancer Ther. 2003 Oct;2(10):1023-9
pubmed: 14578467
Exp Hematol. 2010 Jun;38(6):472-80
pubmed: 20303384
Blood. 2013 Nov 21;122(22):3616-27; quiz 3699
pubmed: 24030381
Blood. 2014 Apr 3;123(14):2220-8
pubmed: 24478400
Transl Cancer Res. 2012 Aug;1(2):88-89
pubmed: 23002429
J Clin Oncol. 2012 Nov 20;30(33):4098-103
pubmed: 23071245
Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S124-9
pubmed: 27521308